Guardant Health (GH) director reports 711 RSUs vest, sells 361 shares at $67.42
Guardant Health director and Chief Information Officer Kumud Kalia reported transactions on Form 4 showing restricted stock units vesting and a small open-market sale.
Rhea-AI Filing Summary
Guardant Health director and Chief Information Officer Kumud Kalia reported transactions on Form 4 showing restricted stock units vesting and a small open-market sale. On 09/01/2025, 711 shares were reported as acquired at a $0 price reflecting the vesting of RSUs, leaving 19,211 shares beneficially owned. The filing also shows a disposal of 361 shares on 09/01/2025 at a price of $67.42, reducing reported holdings to 18,850 shares. The RSU award was originally granted in November 2021 and vests quarterly through the three-year schedule that began 09/01/2022.
Positive
- 711 RSU shares vested on 09/01/2025, reflecting scheduled compensation delivery
- Reported beneficial ownership remains substantial at 19,211 shares immediately after the vesting event
Negative
- 361 shares were sold on 09/01/2025 at $67.42, reducing holdings to 18,850 shares
Insights
TL;DR: Director sold a small number of shares and had RSUs vest; net holdings declined slightly.
The transactions are routine insider activity: vesting of previously granted restricted stock units produced 711 shares reported as acquired at no cash cost, consistent with the award schedule disclosed in the filing. A contemporaneous sale of 361 shares at $67.42 reduced the director's net ownership by 361 shares to 18,850. The scale of the sale (<2% of post-transaction holdings) appears immaterial to company capitalization.
TL;DR: Vesting and a small sale are standard executive compensation events, not indicative of governance issues.
The Form 4 documents an ordinary-course vesting event from a 2021 RSU grant and a partial disposition of shares. The filing includes the RSU vesting schedule (25% vested 09/01/2022, remainder quarterly over three years) which explains the 711-share acquisition. There is no indication of abnormal trading patterns, exceptions, or use of a 10b5-1 plan noted on the face of the form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 711 | $0.00 | $0.00 |
| Exercise | Common Stock | 711 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 361 | $67.42 | $24K |
Footnotes (2)
- F1. Not applicable for Restricted Stock Units.
- F2. The restricted stock unit award was granted on November 2, 2021, and vested 25% of the shares subject to such award on September 1, 2022. The remaining 75% of the shares subject to such award vests in equal installments on each quarterly anniversary of September 1, 2022 during the three-year period thereafter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did Guardant Health (GH) insider Kumud Kalia report on Form 4?
What is the vesting schedule for the RSU award mentioned in the Form 4?
Did the Form 4 indicate use of a 10b5-1 trading plan for these transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.